Orphan Drugs Market Opportunities 2031
Les médicaments orphelins sont des médicaments pharmaceutiques qui restent sous-développés commercialement. Il s'agit de vaccins, de médicaments ou d'agents de diagnostic in vivo, destinés à traiter, diagnostiquer et prévenir une maladie rare.
DYNAMIQUE DU MARCHÉ
Le marché des médicaments orphelins devrait croître selon les prévisions, en raison de facteurs tels que la prévalence des maladies rares, la sensibilisation croissante parmi la population, en augmentant les investissements en R&D, le développement de médicaments, ainsi que les progrès et les innovations.
ÉTENDUE DU MARCHÉ
L'analyse du marché mondial des médicaments orphelins jusqu'en 2031 est une étude spécialisée et approfondie de l'industrie pharmaceutique avec un concentrez-vous sur l’analyse des tendances du marché mondial. Le rapport vise à fournir un aperçu du marché des médicaments orphelins avec une segmentation détaillée du marché par ingrédients actifs, maladie, utilisateur final et géographie. Le marché mondial des médicaments orphelins devrait connaître une forte croissance au cours de la période de prévision. Le rapport fournit des statistiques clés sur l'état du marché des principaux acteurs du marché des médicaments orphelins et présente les principales tendances et opportunités sur le marché.
SEGMENTATION DU MARCHÉ
Le rapport mondial sur les médicaments orphelins Le marché des médicaments est segmenté en fonction des ingrédients actifs, de la maladie et de l’utilisateur final. Sur la base des ingrédients actifs, le marché est segmenté en Obinutuzumab, Lénalidomide, Brentuximab, Vedotin, Riociguat, Ofatumumab, Nelarabine, Bosutinib, Mannitol, Acide carglumique, Aztréonam, chlorhydrate d’histamine, Eliglustat, Cabozantinib, Ramucirumab, Decitabine, Defibrotide. En fonction de la maladie, le marché est segmenté en lymphome hodgkinien, hémoglobinurie paroxystique nocturne, hypertension pulmonaire thromboembolique chronique (CTEPH), leucémie lymphoïde chronique, leucémie myéloïde chronique, leucémie lymphoblastique aiguë à cellules T (T-ALL), leucémie myéloïde chronique à chromosome Philadelphie positif ( Ph+ CML), Mucoviscidose (FK), leucémie myéloïde aiguë, Myélome multiple, Acidémie isovalérique, Maladie de Gaucher de type 1 (GD1), Carcinome médullaire métastatique de la thyroïde, Cancer gastrique avancé ou adénocarcinome de la jonction gastro-œsophagienne, Leucémie myéloïde aiguë (LMA) secondaire , Maladie veino-occlusive hépatique (MVO)/syndrome obstructif sinusoïdal (SOS) sévère. En fonction de l’utilisateur final, le marché est segmenté en hôpitaux et centres chirurgicaux ambulatoires.
Le rapport fournit un aperçu détaillé de l'industrie, comprenant des informations à la fois qualitatives et quantitatives. Il fournit un aperçu et des prévisions du marché mondial des médicaments orphelins en fonction de divers segments. Il fournit également la taille du marché et des estimations prévisionnelles de 2021 à 2031 pour cinq grandes régions, à savoir : Amérique du Nord, Europe, Asie-Pacifique (APAC), Moyen-Orient et Afrique (MEA) et Amérique du Sud et du Sud. Amérique centrale. Le marché des médicaments orphelins de chaque région est ensuite sous-segmenté par pays et segments respectifs. Le rapport couvre l'analyse et les prévisions de 18 pays dans le monde ainsi que les tendances actuelles et les opportunités qui prévalent dans la région.
Le rapport analyse les facteurs affectant le marché des médicaments orphelins du côté de la demande et de l'offre et évalue plus en détail la dynamique du marché affectant le marché des médicaments orphelins. marché au cours de la période de prévision, c’est-à-dire les moteurs, les contraintes, les opportunités et les tendances futures. Le rapport fournit également une analyse PEST exhaustive pour les cinq régions, à savoir : Amérique du Nord, Europe, APAC, MEA et Amérique du Sud et du Sud. Amérique centrale après avoir évalué les facteurs politiques, économiques, sociaux et technologiques affectant le marché des médicaments orphelins dans ces régions.
ACTEURS DU MARCHÉ
Le les rapports couvrent les développements clés du marché des médicaments orphelins en tant que stratégies de croissance organique et inorganique. Diverses entreprises se concentrent sur des stratégies de croissance organique telles que les lancements de produits, les approbations de produits et d'autres telles que les brevets et les événements. Les activités de stratégies de croissance inorganiques observées sur le marché étaient des acquisitions et des partenariats et des partenariats. collaborations. Ces activités ont ouvert la voie à l’expansion des activités et de la clientèle des acteurs du marché. Les payeurs du marché des médicaments orphelins devraient bénéficier d’opportunités de croissance lucratives à l’avenir avec la demande croissante pour le marché des médicaments orphelins sur le marché mondial. Vous trouverez ci-dessous la liste de quelques entreprises engagées sur le marché des médicaments orphelins.
Le rapport comprend également les profils des sociétés du marché des médicaments orphelins ainsi que leur analyse SWOT et leurs stratégies de marché. En outre, le rapport se concentre sur les principaux acteurs de l'industrie avec des informations telles que les profils d'entreprise, les composants et services proposés, les informations financières des 3 dernières années, les développements clés au cours des cinq dernières années.
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Alexion
- CELGENE CORPORATION
- Novartis AG
- Takeda Pharmaceuticals Company Limited
- Biogen
- Bristol-Myers Squibb Company
- Bayer AG
- Sanofi
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Alexion
- CELGENE CORPORATION
- Novartis AG
- Takeda Pharmaceuticals Company Limited
- Biogen
- Bristol-Myers Squibb Company
- Bayer AG
- Sanofi
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For